Image Source: AsiaOne
RedHill Biopharma’s Phase 2/3 COVID-19 Study Approved in Mexico GlobeNewswire August 11, 2020 The global Phase 2/3 study with opaganib is set to enroll up to 270 patients with severe COVID-19 across 40 clinical sites--The global Phase 2/3 study has been approved in Mexico, the UK and Russia and is also under review in Italy, Brazil and additional countries--Enrollment in a parallel U.S. Phase 2 study in patients with severe COVID-19 is approximately 50% complete and is expected to be completed this month--Potential submission of global emergency use applications planned as early as Q4/2020
Source: AsiaOne